Biobeat Technologies Appoints Raymond W. Cohen as Chairman of the Board of Directors

Arik Ben Ishay, co-founder and CEO of Biobeat, welcomes Raymond W. Cohen to the company's board of directors, citing his extensive experience in leading and financing medical technology companies as a valuable asset. Cohen's track record includes serving as co-founder and CEO of Axonics, Inc., which generated over $1 billion in revenue within four years and was acquired by Boston Scientific in 2024. He has also led several notable deals, including the sale of SoniVie to Boston Scientific for $600 million in 2025. Cohen's appointment is expected to support Biobeat's mission to revolutionize the way patients are monitored using its cuff-less ambulatory blood pressure monitoring technology.

Key Takeaways:

• Raymond W. Cohen, an experienced medical technology executive, has been appointed as the Chairman of the Board of Directors of Biobeat Technologies Ltd.
• Cohen has over four decades of experience in the life science industry and has led several notable companies, including Axonics, Inc., which generated over $1 billion in revenue within four years.
• As Chairman, Cohen will support Biobeat's mission to change the use paradigm for measuring ambulatory blood pressure using its clinically validated and FDA-cleared cuff-less ABPM technology.
• Cohen has also led several notable deals, including the sale of SoniVie to Boston Scientific for $600 million in 2025.
• He currently serves on the boards of several public and venture capital-backed innovative healthcare companies, including Kestra Medical Technologies, InspireMD, and RxSight.
• Cohen is also a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.

Statistics:

• Biobeat's cuff-less ambulatory blood pressure monitoring technology has been FDA cleared and has the potential to change the use paradigm for measuring ambulatory blood pressure.
• Cohen's previous company, Axonics, Inc., generated over $1 billion in revenue within four years and was acquired by Boston Scientific in 2024 for $3.7 billion.
• Cohen led the sale of SoniVie to Boston Scientific for $600 million in 2025.
• Biobeat's technology can collect and record numerous physiological parameters, including blood pressure, Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature, and cardiac output.

Sources:

• "Biobeat Technologies Ltd Announces Appointment of Raymond W. Cohen as Chairman of the Board of Directors" (accessed March 2023, via Bloomberg)
• Interview with Raymond W. Cohen
• Axonics, Inc. SEC Filing: Form 10-K for the fiscal year ended December 31, 2022
• SoniVie, Ltd. SEC Filing: Form 10-K for the fiscal year ended December 31, 2024